PAK4 Kinase Activity and Somatic Mutation Promote Carcinoma Cell Motility and Influence Inhibitor Sensitivity

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2012 Jun 13

PMID 22689056

Citations 25

Authors

A D Whale

A Dart

M Holt

G E Jones

C M Wells

Affiliations

Soon will be listed here.

Abstract

Hepatocyte growth factor (HGF) and its receptor (c-Met) are associated with cancer cell motility and invasiveness. p21-activated kinase 4 (PAK4), a potential therapeutic target, is recruited to and activated by c-Met. In response, PAK4 phosphorylates LIM kinase 1 (LIMK1) in an HGF-dependent manner in metastatic prostate carcinoma cells. PAK4 overexpression is known to induce increased cell migration speed but the requirement for kinase activity has not been established. We have used a panel of PAK4 truncations and mutations in a combination of overexpression and RNAi rescue experiments to determine the requirement for PAK4 kinase activity during carcinoma cell motility downstream of HGF. We find that neither the kinase domain alone nor a PAK4 mutant unable to bind Cdc42 is able to fully rescue cell motility in a PAK4-deficient background. Nevertheless, we find that PAK4 kinase activity and associated LIMK1 activity are essential for carcinoma cell motility, highlighting PAK4 as a potential anti-metastatic therapeutic target. We also show here that overexpression of PAK4 harbouring a somatic mutation, E329K, increased the HGF-driven motility of metastatic prostate carcinoma cells. E329 lies within the glycine-rich loop region of the kinase. Our data suggest that E329K mutation leads to a modest increase in kinase activity, conferring resistance to competitive ATP inhibitors in addition to promoting cell migration. The existence of such a mutation may have implications for the development of PAK4-specific competitive ATP inhibitors should PAK4 be further explored for clinical inhibition.

Citing Articles

p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond.

Li X, Li F Cancers (Basel). 2022; 14(19).

PMID: 36230657 PMC: 9563254. DOI: 10.3390/cancers14194736.

Comprehensive analysis of the prognostic implications and functional exploration of PAK gene family in human cancer.

Lei K, Luo M, Tu Z, Lv S, Liu J, Gong C Cancer Cell Int. 2022; 22(1):275.

PMID: 36064705 PMC: 9442929. DOI: 10.1186/s12935-022-02689-6.

CORO1C, a novel PAK4 binding protein, recruits phospho-PAK4 at serine 99 to the leading edge and promotes the migration of gastric cancer cells.

Li X, Chen M, Yuan Y, Li J, Li F Acta Biochim Biophys Sin (Shanghai). 2022; 54(5):673-685.

PMID: 35593474 PMC: 9827817. DOI: 10.3724/abbs.2022044.

Cytoskeletal dynamics regulates stromal invasion behavior of distinct liver cancer subtypes.

Nguyen R, Xiao H, Gong X, Arroyo A, Cabral A, Fischer T Commun Biol. 2022; 5(1):202.

PMID: 35241781 PMC: 8894393. DOI: 10.1038/s42003-022-03121-5.

CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway.

Huang C, Du R, Jia X, Liu K, Qiao Y, Wu Q Cell Death Differ. 2021; 29(1):14-27.

PMID: 34262144 PMC: 8738751. DOI: 10.1038/s41418-021-00828-6.

References

Eswaran J, Soundararajan M, Knapp S . Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev. 2009; 28(1-2):209-17. DOI: 10.1007/s10555-008-9181-4. View

Murray B, Guo C, Piraino J, Westwick J, Zhang C, Lamerdin J . Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010; 107(20):9446-51. PMC: 2889050. DOI: 10.1073/pnas.0911863107. View

Wells C, Whale A, Parsons M, Masters J, Jones G . PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci. 2010; 123(Pt 10):1663-73. PMC: 2864712. DOI: 10.1242/jcs.055707. View

Yoshioka K, Foletta V, Bernard O, Itoh K . A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U S A. 2003; 100(12):7247-52. PMC: 165861. DOI: 10.1073/pnas.1232344100. View

Barouch-Bentov R, Che J, Lee C, Yang Y, Herman A, Jia Y . A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol Cell. 2009; 33(1):43-52. PMC: 2683036. DOI: 10.1016/j.molcel.2008.12.024. View

Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O . The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun. 2004; 319(4):1272-5. DOI: 10.1016/j.bbrc.2004.05.113. View

Eswaran J, Lee W, Debreczeni J, Filippakopoulos P, Turnbull A, Fedorov O . Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure. 2007; 15(2):201-13. PMC: 1885963. DOI: 10.1016/j.str.2007.01.001. View

Zhao Z, Manser E . Do PAKs make good drug targets?. F1000 Biol Rep. 2010; 2:70. PMC: 2989626. DOI: 10.3410/B2-70. View

Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee H . The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res. 2008; 6(7):1215-24. PMC: 2822623. DOI: 10.1158/1541-7786.MCR-08-0087. View

10.

Soosairajah J, Maiti S, Wiggan O, Sarmiere P, Moussi N, Sarcevic B . Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. EMBO J. 2005; 24(3):473-86. PMC: 548651. DOI: 10.1038/sj.emboj.7600543. View

11.

Lai A, Abella J, Park M . Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009; 19(10):542-51. DOI: 10.1016/j.tcb.2009.07.002. View

12.

Baldassa S, Calogero A, Colombo G, Zippel R, Gnesutta N . N-terminal interaction domain implicates PAK4 in translational regulation and reveals novel cellular localization signals. J Cell Physiol. 2010; 224(3):722-33. DOI: 10.1002/jcp.22172. View

13.

Ahmed T, Shea K, Masters J, Jones G, Wells C . A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 2008; 20(7):1320-8. DOI: 10.1016/j.cellsig.2008.02.021. View

14.

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

15.

Lai F, Szczodrak M, Block J, Faix J, Breitsprecher D, Mannherz H . Arp2/3 complex interactions and actin network turnover in lamellipodia. EMBO J. 2008; 27(7):982-92. PMC: 2265112. DOI: 10.1038/emboj.2008.34. View

16.

Siu M, Chan H, Kong D, Wong E, Wong O, Ngan H . p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A. 2010; 107(43):18622-7. PMC: 2972956. DOI: 10.1073/pnas.0907481107. View

17.

Knudsen B, Vande Woude G . Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev. 2008; 18(1):87-96. DOI: 10.1016/j.gde.2008.02.001. View

18.

Paliouras G, Naujokas M, Park M . Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Mol Cell Biol. 2009; 29(11):3018-32. PMC: 2682017. DOI: 10.1128/MCB.01286-08. View

19.

Scott R, Hooper S, Crighton D, Li A, Konig I, Munro J . LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol. 2010; 191(1):169-85. PMC: 2953444. DOI: 10.1083/jcb.201002041. View

20.

Kimmelman A, Hezel A, Aguirre A, Zheng H, Paik J, Ying H . Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008; 105(49):19372-7. PMC: 2614768. DOI: 10.1073/pnas.0809966105. View